Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26633418 | 0.89 | DDB1 (0.59) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL27089927 | 0.89 | DDB1 (0.59) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL30631086 | 0.89 | DDB1 (0.59) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL29257881 | 0.84 | DDB1 (0.50) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL30830916 | 0.84 | DDB1 (0.52) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL25187964 | 0.82 | CRBN (0.67) | DDB1CRBNNAMPTPOLB | |
| SCHEMBL23301622 | 0.82 | CRBN (0.67) | DDB1CRBNNAMPTPOLB | |
| SCHEMBL24206650 | 0.82 | CRBN (0.67) | DDB1CRBNNAMPTPOLB | |
| SCHEMBL31323392 | 0.82 | DDB1 (0.48) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL25447032 | 0.82 | DDB1 (0.66) | DDB1CRBNNAMPTPDK4CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619404-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-06-13 | — | — | US | disclosed |
| WO-2024107711-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235698-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | ADRM1, BRDT, RBX1 | DDB1 144/4885CRBN 82/4885NAMPT 3502/4885 |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | DDB1 2514/4885CRBN 929/4885NAMPT 1807/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | DDB1 353/4885CRBN 37/4885NAMPT 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.